SC-AMBIOPHARM
30.6.2020 22:22:10 CEST | Business Wire | Press release
AmbioPharm Inc. a leading supplier of peptide active pharmaceutical ingredients has recently opened its new manufacturing and quality control facilities at its headquarters in South Carolina. “The new buildings were completed in April and qualified by May 15, 2020 expanding our peptide manufacturing capacity,” stated Dr. Chris J. Bai, CEO. “The new buildings add nearly 56,000 sq. ft of production space to our current footprint in South Carolina. In the near future, our subsidiary site in Shanghai will also complete a new campus of 350,000 sq. ft. later this year,” stated Dr. Bai.
“As the world battles the Covid-19 pandemic, it has become increasingly apparent that no single solution will suffice for patients who are fighting the disease. Peptide approaches have been recently advanced for potential vaccine development, diagnostic testing and as therapeutic agents to help ameliorate the cytokine storm,” stated Dr. Michael W. Pennington, CSO. “Furthermore, we believe that science will prove to be the Achilles’ heel of the virus, and the world will recover more quickly as better therapies become available,” added Dr. Pennington.
AmbioPharm Inc. is uniquely positioned to help companies that are developing peptide-based approaches targeting the virus. As the company with the world’s largest cGMP peptide manufacturing capacity, AmbioPharm Inc. has a very unique business model which helps us to produce peptides of both high quality and purity with very economical cost. AmbioPharm Inc. can be contacted through our website if you have a project which requires our services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630006013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Electronics and ASML Expand Strategic Collaboration for Next-Generation Semiconductor Manufacturing8.9.2026 13:51:00 CEST | Press release
Samsung joins industry initiative for 12-inch photomask platform for High NA EUVSamsung reinforces leadership with planned High NA EUV adoption for future DRAM manufacturing for the first time in the industry Samsung Electronics and ASML today announced an expansion of their long-standing strategic partnership, deepening collaboration on High NA EUV lithography and advanced semiconductor manufacturing technologies that will help drive the next generation of innovation in the AI era. Building on years of successful cooperation, the companies will work together to accelerate the development and deployment of technologies that support the increasing performance and efficiency requirements of advanced semiconductor manufacturing. Samsung will join the industry initiative to advance next-generation 12-inch photomask technology for future manufacturing. The semiconductor industry has relied on the 6-inch photomask format for decades. With High NA EUV, the transition to larger, 12-inch masks
Hovione Appoints Stefan Doboczky as Chief Executive Officer8.9.2026 13:16:00 CEST | Press release
Chairman of the Board of Directors Stefan Doboczky to take over operational leadership of the family-owned pharmaceutical technology and services group on April 1, 2027 Hovione Holding AG today announced the appointment of Stefan Doboczky as Chief Executive Officer (CEO), effective April 1, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908358544/en/ Stefan Doboczky, Chief Executive Officer of Hovione. Photo credit: Karl Michalski. Stefan Doboczky has served as Chairman of the Board of Directors of Hovione Holding AG since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman on assuming the role of Chief Executive Officer. Founded in 1959, Hovione is a family-owned pharmaceutical technology and services group serving the industry worldwide, with more than 2,600 employees, four FDA-inspected production and R&D sites in Europe, the United States and China, an
Hirect to Showcase In-House Developed 6,000 HP Electric Locomotive Propulsion System and Indian Railways Contract at InnoTrans 20268.9.2026 13:09:00 CEST | Press release
Vertically integrated propulsion systems provider announces first full MEMU trainset system order Hirect (NSE: HIRECT), a premier manufacturer of heavy-duty electrical and power electronic systems for rail network rolling stock, will debut its new 6,000 HP locomotive propulsion system at InnoTrans 2026, Berlin, 22 - 25 September. The company will also announce the first development order for the complete trainset propulsion system, which will deliver the power and traction package for Indian Railways' next-generation Mainline Electric Multiple Unit (MEMU) fleet. Hirect's 6,000 HP electric locomotive propulsion system — designed, engineered and manufactured entirely in-house, including its liquid-cooled IGBT traction inverters/converters and proprietary control software — completed its acceptance regime this year after successfully hauling loaded freight in a WAG-9 locomotive under India's severe duty cycles and demanding thermal operating environment. The qualification opens one of the
NIQ Expands Product Intelligence Across Western Europe, Strengthening the Foundation for AI-Driven Commerce8.9.2026 12:32:00 CEST | Press release
Enhanced capabilities connect product attributes with market performance, helping brands and retailers understand shopper choice today and prepare for AI-mediated discovery NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of NIQ Product Insights (NPI) across Western Europe, strengthening its Product Intelligence portfolio to help brands and retailers better understand what drives shopper choice and category growth. The expansion brings enhanced product intelligence capabilities to Austria, Belgium, Italy, Netherlands, Portugal, Spain and Switzerland, building on existing availability in France, Germany, Ireland, and the United Kingdom. As shoppers, and increasingly the digital and AI-powered tools that guide them, evaluate products against specific health, wellness, sustainability, and ingredient preferences, product attributes are becoming an increasingly important part of commerce’s intelligence infrastructure. Brands and retailers need more tha
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 20268.9.2026 12:30:00 CEST | Press release
Compass will debut Change the Tune in TRD, a new U.S. healthcare provider (HCP) education campaign for treatment-resistant depression (TRD) at Booth #901Seven poster presentations include new health economics and outcomes research (HEOR) data alongside encore analyses from the COMP360 clinical development program Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical development program. Change the Tune in TRD: Advancing HCP Education Change the Tune in TRD is a new educational initiative for U.S. HCPs exploring the neurobiology and navigating care pathways in TRD.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom